Search

Bo Peng

Examiner (ID: 15510)

Most Active Art Unit
1648
Art Unit(s)
1648, CQIC, 4171, 4111
Total Applications
343
Issued Applications
135
Pending Applications
38
Abandoned Applications
170

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16949454 [patent_doc_number] => 20210208145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR TRIPLE-NEGATIVE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/207165 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17207165 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/207165
DIAGNOSTIC AND THERAPEUTIC METHODS FOR TRIPLE-NEGATIVE BREAST CANCER Mar 18, 2021 Abandoned
Array ( [id] => 18352044 [patent_doc_number] => 20230140155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER [patent_app_type] => utility [patent_app_number] => 17/910544 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910544 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/910544
MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER Mar 10, 2021 Pending
Array ( [id] => 17428437 [patent_doc_number] => 20220056145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => ANTI-CD39 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/197097 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17197097 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/197097
ANTI-CD39 ANTIBODIES Mar 9, 2021 Abandoned
Array ( [id] => 16961580 [patent_doc_number] => 20210213079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS [patent_app_type] => utility [patent_app_number] => 17/193511 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193511 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/193511
TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS Mar 4, 2021 Pending
Array ( [id] => 18335588 [patent_doc_number] => 20230127536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => TARGETING TIM-3 AND LAG-3 RECEPTORS INDUCED BY CD44+ CD90+ CANCER STEM CELLS IN SMALL CELL LUNG CANCER [patent_app_type] => utility [patent_app_number] => 17/917956 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2982 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917956 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/917956
TARGETING TIM-3 AND LAG-3 RECEPTORS INDUCED BY CD44+ CD90+ CANCER STEM CELLS IN SMALL CELL LUNG CANCER Mar 3, 2021 Pending
Array ( [id] => 18264641 [patent_doc_number] => 20230085883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/802124 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802124 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/802124
Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy Mar 2, 2021 Issued
Array ( [id] => 19121065 [patent_doc_number] => 11965036 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Bispecific antigen-binding constructs targeting HER2 [patent_app_type] => utility [patent_app_number] => 17/184508 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 121 [patent_no_of_words] => 52180 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184508 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/184508
Bispecific antigen-binding constructs targeting HER2 Feb 23, 2021 Issued
Array ( [id] => 18620452 [patent_doc_number] => 11753480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Anti-SIRP-alpha antibodies and related methods [patent_app_type] => utility [patent_app_number] => 17/182081 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27715 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17182081 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/182081
Anti-SIRP-alpha antibodies and related methods Feb 21, 2021 Issued
Array ( [id] => 18250677 [patent_doc_number] => 20230077716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => ANTIBODIES PROTECTIVE AGAINST INFLUENZA B [patent_app_type] => utility [patent_app_number] => 17/798261 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798261 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/798261
ANTIBODIES PROTECTIVE AGAINST INFLUENZA B Feb 4, 2021 Abandoned
Array ( [id] => 19503858 [patent_doc_number] => 12115256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Targeted liposomal gemcitabine and methods thereof [patent_app_type] => utility [patent_app_number] => 17/165534 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 15690 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165534 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/165534
Targeted liposomal gemcitabine and methods thereof Feb 1, 2021 Issued
Array ( [id] => 17300918 [patent_doc_number] => 20210396757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => COMPOSITIONS AND METHODS FOR FLUID BIOPSY OF MELANOMA [patent_app_type] => utility [patent_app_number] => 17/160171 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17160171 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/160171
COMPOSITIONS AND METHODS FOR FLUID BIOPSY OF MELANOMA Jan 26, 2021 Abandoned
Array ( [id] => 16848166 [patent_doc_number] => 20210148911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => Methods and Diagnostics for Cancer Detection and Treatment Monitoring [patent_app_type] => utility [patent_app_number] => 17/159480 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159480 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/159480
Methods and Diagnostics for Cancer Detection and Treatment Monitoring Jan 26, 2021 Abandoned
Array ( [id] => 18195506 [patent_doc_number] => 20230049025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => ENGINEERED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 17/759222 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759222 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/759222
ENGINEERED IMMUNE CELLS Jan 20, 2021 Pending
Array ( [id] => 18596090 [patent_doc_number] => 20230270881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => ONCOGENIC TRIM37 IS A TARGETABLE EPIGENETIC DRIVER OF METASTASIS AND LINKS CHEMORESISTANCE AND METASTATIC FATE IN TRIPLE-NEGATIVE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/794432 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17794432 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/794432
ONCOGENIC TRIM37 IS A TARGETABLE EPIGENETIC DRIVER OF METASTASIS AND LINKS CHEMORESISTANCE AND METASTATIC FATE IN TRIPLE-NEGATIVE BREAST CANCER Jan 20, 2021 Pending
Array ( [id] => 16854967 [patent_doc_number] => 20210155712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => TREATMENT AND PREVENTION OF CANCER USING HER3 ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/153705 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153705 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/153705
Treatment and prevention of cancer using HER3 antigen-binding molecules Jan 19, 2021 Issued
Array ( [id] => 18195475 [patent_doc_number] => 20230048994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => RECOMBINANT AAV PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/793196 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -98 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793196 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/793196
RECOMBINANT AAV PRODUCTION Jan 14, 2021 Pending
Array ( [id] => 17170435 [patent_doc_number] => 20210324105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => BISPECIFIC ANTIBODIES AGAINST HER2 [patent_app_type] => utility [patent_app_number] => 17/149019 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149019 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/149019
BISPECIFIC ANTIBODIES AGAINST HER2 Jan 13, 2021 Abandoned
Array ( [id] => 20466847 [patent_doc_number] => 12522880 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => RT-PCR detection method and kit for novel coronavirus [patent_app_type] => utility [patent_app_number] => 17/905662 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 838 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905662 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/905662
RT-PCR detection method and kit for novel coronavirus Dec 29, 2020 Issued
Array ( [id] => 18739637 [patent_doc_number] => 20230348599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => METHODS FOR TREATING GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 17/786917 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786917 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/786917
METHODS FOR TREATING GLIOBLASTOMA Dec 16, 2020 Pending
Array ( [id] => 18196930 [patent_doc_number] => 20230050449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/785590 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785590 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/785590
METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS Dec 15, 2020 Abandoned
Menu